BIRMINGHAM, Ala., Sept. 17 /PRNewswire/ -- Detailed cholesterol testing for Type 2 diabetes patients is the focus of a newly published article by Atherotech Diagnostics Lab Chief Medical Officer Michael E. Cobble, M.D. "Advanced Lipid Testing" appears in the September/October 2010 quarterly issue of Practical Diabetology.
The article discusses the clinical advantages of advanced cholesterol testing in reducing cardiovascular disease (CVD) risk in patients with Type 2 diabetes and details several currently available advanced lipid tests, including the VAP® Cholesterol Test from Atherotech. Cobble also explores which patients are appropriate to test and how to apply advanced lipid testing results.
Advanced lipid testing is affordable, widely available and may provide valuable information in the treatment and management of people living with Type 2 diabetes, explained Cobble, who is also a director, researcher and clinician at Canyons Medical Center in Sandy, Utah.
"We know that aggressive management of multiple cardiovascular disease risks in diabetes mellitus patients has proven beneficial," Cobble said. "But in order to properly treat these patients, we first must identify them and effectively assess their risk. This is achieved through advanced lipid profiles."
Diabetes is a high-risk CVD condition that affects more than 24 million Americans, and patients with Type 2 diabetes are considered high risk due to traditional CVD risk factors and residual lipid risk factors, all of which can be determined through detailed lipoprotein assays such as the VAP Test.
"Standard lipid tests miss more than half of all at-risk patients, and may actually